EN DE
Watch Lumos Diagnostics Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lumos Diagnostics Holdings Ltd (LDX) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Lumos Diagnostics Holdings Ltd stock A$0.06, price A$0.07, that is 13.9% below the price, quality 22 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · Based in US · ISIN AU0000157091

LD Lumos Diagnostics Holdings Ltd logo Thin data Nov 10, 2026

Lumos Diagnostics Holdings Ltd

LDX · AU
Expensive, weak quality

Our calculation puts a fair price 14% below what the stock costs today.

Revenue last quarter +16% vs. a year ago.
Fair value A$0.0629 · Overvalued
Quality 22/100
Weak Growth (revenue 5y −6.5 %/yr in USD)
Loss-making · -37.5% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Lumos Diagnostics Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$1.22 A$0.0100 Fair Value A$0.0629 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0100 – A$1.22 · fair‑value band A$0.0524 – A$0.0734 · the A$0.0730 price screens above the A$0.0629 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Lumos Diagnostics Holdings in your weekly email

Every Wednesday you see whether Lumos Diagnostics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States.

Show moreShow less

The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.

Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.

Stock analysis

Lumos Diagnostics Holdings Ltd (LDX) currently trades at A$0.0730, while our estimate is A$0.0629, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0524 (bear) to A$0.0734 (bull), the price of A$0.0730 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Lumos Diagnostics Holdings Ltd reported revenue of $13.5M in FY2025 versus $11.6M in FY2021, a compound +3.8%/yr. Reported net income was −$5.1M in FY2025.

Key figures

Market cap A$68.9M (≈ $47.4M) Micro · P/S ratio 4.49 · EPS (TTM) A$−0.0100 · Net margin −37.5% · Return on equity −34.1% · Return on assets (EBIT) −38.0% (5-year average) · Operating margin −108% · Revenue (TTM) $13.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −14%, LDX screens richer than that median.

Fair Value

Bear A$0.0524 Fair Value A$0.0629 Bull A$0.0734
Price A$0.0730 · Downside -13.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 29
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 6
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+7.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.5%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−58.4% (2020) → −107.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LDX screens overvalued: fair value 14% below the price. Compare with Abbott Laboratories, →

Compare Lumos Diagnostics Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −13.8% · Below median
Profitability
Return on assets −12.4% · Below median
Net margin (12 months) −37.5% · Bottom 25%
Operating margin (12 months) −107.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 16.0% · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.08× · Cheaper than median
P/S (12 months) 3.60× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 17
FUTURE (revenue growth)80 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs LDX
DexCom, Inc DXCM $79.92 $89.18 +12% vs LDX
Stryker Corporation SYK $324.29 $358.30 +10% vs LDX
STERIS plc STE $257.12 $279.53 +9% vs LDX
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs LDX
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs LDX
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs LDX
Abbott Laboratories, ABT $110.46 $75.28 −32% vs LDX
Medtronic plc MDT $101.59 $65.61 −35% vs LDX
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs LDX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lumos Diagnostics Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lumos Diagnostics Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/LDX

Frequently asked questions

Is Lumos Diagnostics Holdings Ltd (LDX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0629 versus a price of A$0.0730, about 14% lower (overvalued).
What is the fair value of LDX?
Our estimate for Lumos Diagnostics Holdings Ltd is A$0.0629 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0730.
What is the quality score of LDX?
Lumos Diagnostics Holdings Ltd has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lumos Diagnostics Holdings Ltd (LDX)?
Our calculated price target is the estimate of A$0.0629 (as of Nov 10, 2026). Cautious scenario A$0.0524, optimistic scenario A$0.0734. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Lumos Diagnostics Holdings Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.0629, about 14% lower versus a price of A$0.0730 (overvalued). Cautious scenario A$0.0524, optimistic scenario A$0.0734. The calculation is refreshed regularly with new filings.
What is the revenue of Lumos Diagnostics Holdings Ltd (LDX)?
Lumos Diagnostics Holdings Ltd reported trailing-twelve-month revenue of about $13.2M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Lumos Diagnostics Holdings Ltd (LDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lumos Diagnostics Holdings Ltd it is A$0.0629 per share (as of Nov 10, 2026), against a price of A$0.0730.
Is Lumos Diagnostics Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, LDX trades above its calculated fair value: price A$0.0730, fair value A$0.0629, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LDX?
No. The price is what the market pays today (A$0.0730); the fair value is what the company's own numbers justify (A$0.0629). For Lumos Diagnostics Holdings Ltd the two are A$0.0101 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lumos Diagnostics Holdings Ltd worth?
The market values Lumos Diagnostics Holdings Ltd at about A$68.9M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0730; our models calculate a fair value of A$0.0629 per share.
What do the bullish and bearish scenarios say about LDX?
Our models span a range for Lumos Diagnostics Holdings Ltd: cautious scenario A$0.0524, base A$0.0629, optimistic A$0.0734 per share (as of Nov 10, 2026, price A$0.0730). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lumos Diagnostics Holdings Ltd (LDX)?
Balance-sheet figures for Lumos Diagnostics Holdings Ltd (as of Nov 10, 2026): return on equity −34.1%. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is LDX from its 52-week high?
Lumos Diagnostics Holdings Ltd trades at A$0.0730, about 77% below its 52-week high of A$0.3200 and 28% above the low of A$0.0570 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0629 is for.
Which stocks are comparable to Lumos Diagnostics Holdings Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lumos Diagnostics Holdings Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0730, calculated fair value A$0.0629 (−14%), Quality Score 22/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Lumos Diagnostics Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lumos Diagnostics Holdings Ltd (LDX)?
The closing price on Nov 11, 2026 was A$0.0730. Our estimate is A$0.0629, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lumos Diagnostics Holdings Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Lumos Diagnostics Holdings Ltd

How large is the market capitalisation of Lumos Diagnostics Holdings Ltd (LDX)?
The market capitalisation of Lumos Diagnostics Holdings Ltd is A$68.9M (≈ $47.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lumos Diagnostics Holdings Ltd (LDX)?
The price-to-sales ratio of Lumos Diagnostics Holdings Ltd is 4.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lumos Diagnostics Holdings Ltd (LDX)?
Earnings per share at Lumos Diagnostics Holdings Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lumos Diagnostics Holdings Ltd (LDX)?
The net margin of Lumos Diagnostics Holdings Ltd is −37.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lumos Diagnostics Holdings Ltd (LDX)?
The return on equity (ROE) of Lumos Diagnostics Holdings Ltd is −34.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lumos Diagnostics Holdings Ltd (LDX)?
On an EBIT basis the return on assets of Lumos Diagnostics Holdings Ltd is −38.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lumos Diagnostics Holdings Ltd (LDX)?
The operating margin of Lumos Diagnostics Holdings Ltd is −108% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lumos Diagnostics Holdings Ltd (LDX)?
Revenue at Lumos Diagnostics Holdings Ltd is growing +16.0% versus a year earlier (3y avg +8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lumos Diagnostics Holdings Ltd (LDX) generate?
The free cash flow of Lumos Diagnostics Holdings Ltd is −$1.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lumos Diagnostics Holdings Ltd (LDX) hold?
Lumos Diagnostics Holdings Ltd holds more cash than debt, $9.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lumos Diagnostics Holdings Ltd in the live analysis

One click puts Lumos Diagnostics Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.